Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Early screening to find gestational diabetes in pregnancy

Official title: Early Detection of Gestational Diabetes Mellitus in Pregnancy: A Randomized Trial

Run by University of Massachusetts, Worcester · NCT05388643 · Data updated 2026-11-12

This project tries a first-trimester blood screening to see if it finds gestational diabetes earlier in pregnant people at high risk.

More Gestational Diabetes Mellitus in Pregnancy trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment80 (estimated)
SponsorUniversity of Massachusetts, Worcester
Academic / other
Locations1 site (Worcester, Massachusetts)
StatusRecruiting
StartedJuly 1, 2025
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedApril 6, 2026
Trial IDNCT05388643 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Pregnant people aged 18 or older with a singleton pregnancy at or before 12 weeks, receiving prenatal care and planning delivery at UMMHC, who meet ACOG high-risk criteria and speak English or Spanish are ideal candidates.

Probably not a fit

People with preexisting diabetes, those unable to complete an oral glucose tolerance test, those on systemic steroids, or those planning care outside UMMHC are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Gestational diabetes increases risks for both mothers and newborns and is typically screened for in the second trimester. This pilot randomized controlled trial will enroll 80 high-risk pregnant people before 12 weeks at UMass Memorial; half will receive a protocolized first-trimester serum biomarker screen and half will receive standard screening at 24–28 weeks with possible early screening at provider discretion. The study will test the feasibility and acceptability of implementing early screening and compare timing of detection and related maternal and neonatal outcomes. Investigators will use clinical data and participant feedback to refine the protocol for potential broader use.

Why it matters

Potential benefit: If successful, earlier detection could allow earlier treatment and monitoring to reduce pregnancy and newborn complications.

How similar studies have gone: Prior work on first-trimester biomarker screening for gestational diabetes has shown mixed results, so this pilot focuses on feasibility and implementation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1\) age greater than or equal to 18 years old,
* 2\) singleton gestation less than or equal to 12 weeks at initial obstetric visit,
* 3\) receiving prenatal care at UMMHC and plans to deliver at UMMHC,
* 4\) able and willing to provide informed consent,
* 5\) English or Spanish speaking, and
* 6\) are at high risk for developing GDM by ACOG clinical risk factor guidelines.

Exclusion Criteria:

* 1\) known diagnosis of pre-existing pregestational diabetes,
* 2\) plan to receive prenatal care or deliver outside of UMMHC,
* 3\) inability to complete oral glucose tolerance test (e.g. gastric bypass surgery history, gastric dumping syndrome history, vomiting of oral glucose tolerance test), or
* 4\) systemic steroid use.

Where it's running

  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.